Side-by-side · Research reference

ChonlutenvsTriptorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED8/38 cited

BFDA-ApprovedHUMAN-REVIEWED16/64 cited

Chonluten

Khavinson Bioregulator · Bronchial Mucosa

BronchialTarget tissue

In vitroEvidence tierAvolio 2022

THP-1Model systemAvolio 2022

Oral · Sublingual · Per Protocol

Triptorelin

GnRH Agonist · FDA-Approved

3.75–22.5 mgDepot dose rangeYee 2025 Chen 2024

<50 ng/dLTestosterone target

1–6 monthsDepot durationYee 2025 Chen 2024

IM · Depot Injection · Monthly to 6-MonthlyYee 2025

01Mechanism of Action

Parameter

Chonluten

Triptorelin

Primary target

Bronchial epithelial cells and respiratory mucosa tissue complexes

Pituitary GnRH receptorsUnknown 2012

Pathway

Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022

GnRH receptor agonism → initial flare (LH/FSH spike) → receptor desensitization → sustained LH/FSH suppression

Downstream effect

Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022

Castration-level suppression of testosterone (men) and estrogen (women) within 2–4 weeks post-flare

Feedback intact?

—

No — bypasses physiological pulsatility; continuous agonism produces paradoxical suppression

Origin

Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology

Synthetic decapeptide analogue of native GnRH with amino acid substitutions for enhanced receptor affinity and stability

Antibody development

—

02Dosage Protocols

Parameter

Chonluten

Triptorelin

Typical protocol dose

10–20 mg / day

Russian bioregulator tradition dosing; not standardized in Western literature.

—

Frequency

Once or twice daily

Every 1, 3, or 6 months per formulation

Route

Oral (capsule) or sublingual

Sublingual claimed for enhanced bioavailability; not validated.

—

Evidence basis

In vitro mechanistic

Multiple Phase 3 RCTs · FDA-approved 1999

Duration

10–30 days per cycle

Traditional Khavinson protocol; cyclic administration common.

—

Clinical validation

None (PubMed indexed)

—

1-month depot

—

3.75 mg IM

Most common formulation for prostate cancer.

3-month depot

—

11.25 mg IMYee 2025

Reduced injection frequency.

6-month depot

—

22.5 mg IMYee 2025 Chen 2024

Long-acting formulation; improved adherence in real-world use.Yee 2025

Administration route

—

Intramuscular (IM) — gluteal or deltoid

Indication: Prostate cancer

—

Advanced (metastatic or locally advanced)

Androgen deprivation therapy (ADT) backbone.

Indication: Endometriosis

—

3.75 mg monthly

FDA-approved; typically 6-month course.

Indication: Central precocious puberty

—

Pediatric use (≥2 years)Jia 2025

Weight-based dosing per FDA label.

Duration (prostate cancer)

—

Continuous or intermittent ADT protocolsPreston 2024

Intermittent ADT may reduce side effects; cardiovascular risk similar to continuous.

Monitoring

—

Serum testosterone, PSA (prostate cancer), bone density, lipids, glucose

04Side Effects & Safety

Parameter

Chonluten

Triptorelin

Documented adverse events

No published safety data in PubMed-indexed literature

—

Theoretical risks

Peptide hypersensitivity, GI intolerance (uncharacterized)

—

Drug interactions

Unknown — no pharmacokinetic studies available

—

Pregnancy / lactation

No data — avoid

—

Initial flare symptoms

—

Bone pain, urinary obstruction, spinal cord compression (first 2 weeks)

Antiandrogen co-treatment (bicalutamide) mitigates flare in metastatic disease.

Cardiovascular events

—

MI, stroke, arrhythmia — GnRH agonists show higher CV risk vs antagonists in meta-analysesPatel 2025 Preston 2024

Hot flashes

—

Very common (>60%); vasomotor instability

Bone loss / Osteoporosis

—

Accelerated bone mineral density decline; fracture risk ↑Friedrich 2025

Baseline DEXA scan recommended; bisphosphonates or denosumab may be indicated.

Metabolic syndrome

—

Weight gain, insulin resistance, dyslipidemia, diabetes risk

Sexual dysfunction

—

Erectile dysfunction, loss of libido (expected pharmacological effect)Jia 2025

Injection site reactions

—

Pain, erythema, sterile abscess (rare with depot formulations)

Gynecomastia / Breast tenderness

—

Common (10–20%); peripheral aromatization of residual androgens

Fatigue / Mood changes

—

Anemia, depression, cognitive changes reported in long-term ADT

Hepatotoxicity

—

Transient transaminase elevations; clinically apparent liver injury rare

Racial differences (ADT)

—

Black veterans show higher CV event rates vs White veterans on GnRH agonists

Absolute Contraindications

Chonluten

·Known hypersensitivity to peptide components

Triptorelin

·Hypersensitivity to triptorelin, GnRH, or GnRH agonist analogues
·Pregnancy (Category X)

Relative Contraindications

Chonluten

·Pregnancy and lactation (insufficient data)
·Active malignancy (theoretical bioregulator concern)

Triptorelin

·Active cardiovascular disease — consider GnRH antagonist alternative
·Metastatic vertebral disease with spinal cord compression risk (flare hazard)
·Severe urinary obstruction — may worsen during flare
·Osteoporosis or high fracture risk (requires bone-protective therapy)

05Administration Protocol

Parameter

Chonluten

Triptorelin

1. Preparation

Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.

Choose 1-month (3.75 mg), 3-month (11.25 mg), or 6-month (22.5 mg) depot based on adherence needs and clinical context. 6-month formulation shows improved real-world adherence in Asia-Pacific cohorts.

2. Oral route

Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.

Intramuscular — gluteal or deltoid muscle. Use 21–23G needle. Aspirate to confirm non-vascular placement. Rotate sites with repeat injections.

3. Sublingual route

Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.

For metastatic prostate cancer: co-administer antiandrogen (e.g., bicalutamide 50 mg daily) starting 1 week before first injection and continuing 2–4 weeks to prevent tumor flare.

4. Timing

Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.

Baseline: testosterone, PSA, bone density (DEXA), lipids, glucose. Follow-up: testosterone at 4 weeks (confirm <50 ng/dL castration), PSA monthly × 3, then quarterly. Annual DEXA for bone loss.

5. Cycle protocol

10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.

Store vials at room temperature (20–25 °C), protect from light. Do not freeze. Reconstituted suspension should be used immediately.

6. Intermittent ADT protocol (optional)

—

Some protocols use on-treatment periods (9–12 months) alternating with off-treatment intervals until PSA rises. Cardiovascular risk appears similar to continuous ADT.